SG/CALL/NOVO-NORDISK B/750/0.1/20.12.24 Stock

DE000SU52321

Market Closed - Boerse Frankfurt Warrants 15:46:10 2024-06-28 EDT
3.55 ^EUR	-2.47%

1 month	+32.46%
3 months	+38.13%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart NOVO NORDISK A/S

Chart SG/CALL/NOVO-NORDISK B/750/0.1/20.12.24

Latest news about NOVO NORDISK A/S

India plans incentives for diabetes, obesity drug makers in 2026, government official says	06-28	RE
NOVO NORDISK : UBS gives a Neutral rating	06-28	ZD
European Equities Close Mostly Lower Thursday; Bank of England Warns of 'Sharp Correction' Risk	06-27	MT
Top Midday Stories: Walgreens Shares Tumble on Lower Guidance, Store Closures; SM Energy, NOG to Buy XCL Resources; Uber, Lyft Worker Classification Heads to Massachusetts Ballot	06-27	MT

More news

Quotes 5-day view

Date	Price	Change
24-06-28	3.55	-2.47%
24-06-27	3.64	-.--%
24-06-26	3.64	-4.21%
24-06-25	3.8	+10.47%
24-06-24	3.44	-0.29%

Real-time Boerse Frankfurt Warrants

Last update June 28, 2024 at 03:46 pm

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	NOVO NORDISK A/S
Issuer	Société Générale
WKN	SU5232
ISIN	DE000SU52321
Date issued	2023-12-20
Strike	750 kr
Maturity	2024-12-20 (173 Days)
Parity	10 : 1
Emission price	1.02 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	3.94 €
Lowest since issue	1.01 €
Delta	0x
Omega	0.000000
Premium	0x
Gearing	3.78x
Moneyness	1.341
Difference Strike	-255.6 kr
Difference Strike %	-34.08%
Spread	0.17 €
Spread %	4.66%
Intrinsic value	3.424
Present value	0.1310

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

More about the company